A two-drug combination exhibited durable clinical benefit as second- or third-line treatment for pancreatic cancer, according to a topline data announcement released by one of the agent’s ...

The medieval trading center of Turu-Aygyr lies between 3 and 13 feet below the surface of Lake Issyk-Kul in Kyrgyzstan ...

The vopimetostat + daraxonrasib Phase 1/2 readout shows a 92% objective response rate (11/12) and 90% progression-free ...

Monash University's Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median ...

Investigators evaluated the safety and efficacy of daraxonrasib compared to standard-of-care chemotherapy in patients with ...

Cheniere Energy (LNG) benefits from LNG disruptions and long-term contracts, with strong Q1 results and raised guidance. Read ...

A new pancreatic cancer treatment may finally move the needle on what's proved to be an unforgiving disease. Fred Hutch ...

We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. Revolution Medicines (NASDAQ ...

Treatment with GLP-1 RAs does not appear to reduce the risk for TKR compared with metformin among patients with T2D and ...

Daraxonrasib is effective for patients with RAS-mutant and other metastatic pancreatic ductal adenocarcinomas (mPDACs).

The death rate in the group treated with daraxonrasib was 60% lower than those on chemotherapy. This is hailed as a major ...

Shares of Tango Therapeutics gained after the company reported positive initial data from an ongoing study of a potential treatment for pancreatic cancer. The stock climbed 45% to $29.24 in premarket ...